Workflow
创新药出海
icon
Search documents
国产创新药出海首付款记录再刷新,辉瑞60.5亿美元引进三生制药双抗
Guo Ji Jin Rong Bao· 2025-05-20 09:05
Core Viewpoint - The partnership between Sangfor Biopharma and Pfizer marks a significant milestone in the biopharmaceutical industry, with a total agreement value of up to $60.5 billion for the global development, production, and commercialization rights of SSGJ-707, a dual-target PD-1/VEGF antibody, excluding mainland China [2][5][6]. Group 1: Agreement Details - Sangfor Biopharma retains the rights for SSGJ-707 in mainland China and grants Pfizer an option for commercialization in that region based on agreed financial terms [5][6]. - The agreement includes a non-refundable upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion based on development, regulatory approval, and sales [5][6]. - Additionally, Sangfor will receive a tiered percentage of sales revenue from the licensed regions and Pfizer will purchase $100 million worth of common stock from Sangfor upon the agreement's effective date [6][5]. Group 2: Product and Clinical Insights - SSGJ-707 is developed using Sangfor's proprietary CLF2 platform and targets both PD-1 and VEGF, showing promising results in clinical trials for non-small cell lung cancer (NSCLC) with high objective response rates (ORR) and disease control rates (DCR) [7]. - The drug has received breakthrough therapy designation from the National Medical Products Administration (NMPA) for first-line treatment of PD-L1 positive locally advanced or metastatic NSCLC and has also gained IND approval from the FDA [7]. Group 3: Company Overview and Financial Performance - Sangfor Biopharma is a leading biopharmaceutical company with over 100 national invention patents and more than 40 marketed products across various therapeutic areas [9]. - The company reported a revenue of 9.11 billion yuan in 2024, a year-on-year increase of 16.5%, with a net profit of 2.09 billion yuan, up 35% [9]. - Key products include the recombinant human thrombopoietin (rhTPO) product, which generated approximately 5.06 billion yuan in sales, reflecting a 20.4% increase [9]. Group 4: Strategic Collaborations and Future Prospects - In 2024, Sangfor has achieved multiple collaborations, including partnerships in the oncology sector to enhance the accessibility of innovative chemotherapy drugs [10]. - The company is focused on leveraging its rich pipeline and early investments in blood, oncology, and autoimmune disease sectors, indicating a promising future as it approaches the NDA (New Drug Application) phase [12].
医药股强势猛攻!400亿创新药龙头狂飙36%
Ge Long Hui A P P· 2025-05-20 06:33
三连跌后,港股终于迎来反弹。 周二,港股三大指数高开高走,市场热点轮动加速,生物医药、创新药等板块发起强势猛攻。 | ● 热力图 ○ 列表 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | Wind香港概念板块指数 | | | Wind香港二级行业指数 | | | | | | 影视传媒 | 抗肿瘤 | 创新药 | 本地券商 | 黄金珠宝 | Wind香港电气设 Wind香港医药生 Wind香港家庭用 Wind香港硬件设 Wind香港传 | | | | | | 5.73% | 4.96% | 4.82% | 4.69% | 4.40% | 13.40% | 4.05% | 3.84% | 2.48% | 1.59% | | 智能家居 | 武汉本地 | 生物医疗 | CRO | 智能终端 | Wind香港汽车与 Wind香港电信服 Wind香港环保II Wind香港有色金 Wind香港家中 | | | | | | 3.82% | 3.80% | 3.75% | 3.43% | 3.38% ...
冲击三连阳,创新药盘中大涨!医药迎来反转曙光?
Xin Lang Cai Jing· 2025-05-20 06:33
第二,大中型药企经营业绩向上趋势明显。创新药企业整体已进入扭亏为盈区间,利润转正后未来几年 将进入非线性地高速增长阶段。同时在产业内,外资药企购买中国创新药品种趋势明显,中国创新药资 产在全球视角下处于显著低估,产业趋势临界点有望到来。 第三,政策端有明显支持的新动作。今年医保谈判时间提前,医保谈判和丙类目录调整同步进行,丙类 目录主要纳入创新程度高的产品,展现国家支持创新药发展、支持商保作为第二支付手段的决心。 上支付宝APP搜:天弘恒生沪深港创新药精选50ETF联接(C类:014565)一键打包三地创新药龙头 股,天弘国证生物医药ETF联接(C类:011041)汇聚医药各行业龙头,有望助您把握本轮医药反弹行 情。 【后市解读:医药板块后市怎么看?—天弘基金】 4月以来,市场风向开始逐渐转向创新药,创新药相关指数在全市场表现靠前。天弘基金认为:基于基 本面和估值的角度,医药是当前全市场性价比非常高的行业。 第一,看好国产创新药的整体机会。总体上创新药产业已经历 4 年下行,前期医保谈判导致预期过度悲 观,目前政策转向空间及需求相对迫。过去几个月,行业内始终有对优化药品集采政策的广泛讨论和相 应的优化方案征求 ...
创新药出海交易首付款破纪录!可T+0交易的港股创新药ETF(159567)现涨4.23%,三生制药涨超35%
Xin Lang Cai Jing· 2025-05-20 06:33
消息面上,5月20日,港股创新药企三生制药与海外辉瑞公司签订重大许可协议,授予辉瑞在全球(不 包括中国内地)独家开发、生产及商业化双抗的权利。根据协议,三生制药将获得12.5亿美元首付款, 并可能获得高达48亿美元的里程碑付款,以及双位数百分比的销售提成。这一交易再次刷新了国产创新 药出海首付款金额纪录。近期创新药行业利好不断。2025年第一季度,中国创新药license-out交易已有 41起,总金额达369.29亿美元,仅3个月已接近2023年全年水平。 相关产品:港股创新药ETF(159567)、创新药ETF(159992) 大而全:创新药ETF(159992)跟踪创新药指数,该指数布局创新药产业链龙头企业,既汇聚全球CXO 龙头企业,又包含国内仿创药企龙头,有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 国元证券认为,上周医药板块受特朗普宣布将推动美国处方药价格与"其他发达国家"对标政策影响,创 新药细分领域出现回调。特朗普提出行政令计划,旨在使美国药价下降30%-80%,并允许患者直接从制 造商购买药物,绕过中间商。然而,分析指出该政策实施难度较大,美国医药市场 ...
三生制药斩获辉瑞60亿美元大单,带飞港股创新药板块,“三生制药”含量最高的ETF找到了!
Ge Long Hui· 2025-05-20 06:30
Group 1 - The Hong Kong innovative drug sector experienced significant growth, with notable stock increases for companies such as Sangfor Pharma (up 36%), CSPC Pharmaceutical (up over 8%), and others [1] - Various ETFs tracking the innovative drug sector also saw substantial gains, with increases ranging from 4.72% to 5.23% [1][3] Group 2 - Sangfor Pharma announced a licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody SSGJ-707, which includes an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion [5] - This licensing deal sets a new record for upfront payments for Chinese bispecific antibodies, indicating strong market interest [5][6] Group 3 - The trend of Chinese innovative drug companies expanding internationally continues, with multiple successful licensing deals occurring despite recent trade tensions [7] - Recent examples include CSPC Pharmaceutical's licensing of irinotecan liposome injection to Cipla USA for $15 million upfront and potential milestone payments exceeding $1 billion [8] Group 4 - Market analysts believe that multinational corporations' interest in acquiring Chinese innovative drug assets remains strong, which will drive further international expansion [11] - Upcoming ASCO conference will feature significant data releases from several innovative drug companies, including Sangfor Pharma and Innovent Biologics [11] Group 5 - The innovative drug sector is expected to enter a rapid growth phase, driven by commercialization efforts and licensing agreements, which will enhance revenue and accelerate profitability [12] - Sangfor Pharma holds a significant weight in various indices, with a 4.38% share in the Hang Seng Hong Kong Stock Connect Innovative Drug Index [12][17] Group 6 - Analysts predict that high-quality innovative drug companies are entering a profitability cycle, supported by continuous performance releases and favorable policies [19] - The overall supply-demand dynamics in the industry are improving, suggesting a favorable investment opportunity in the sector [19]
暴涨30%!400亿创新药龙头大消息
Zhong Guo Ji Jin Bao· 2025-05-20 02:43
中国基金报记者卢鸰 中国创新药出海又有大消息。 5月20日早间,三生制药(01530.HK)发布公告称,公司及附属子公司沈阳三生、三生国健与辉瑞签署 协议,将向辉瑞独家授予公司自主研发的突破性PD-1/VEGF双特异性抗体SSGJ-707在全球(不包括中 国内地)的开发、生产、商业化权利。公司及沈阳三生将保留SSGJ-707在中国内地的开发、生产、商 业化权利,并基于届时商定的财务条款,授予辉瑞对SSGJ-707在中国内地开展商业化的选择权。 根据协议,三生制药将获得12.5亿美元不可退还且不可抵扣的首付款,以及最高可达48亿美元的开发、 监管批准和销售里程碑付款。公司还将根据授权地区的产品销售额收取两位数百分比的梯度销售分成。 此外,辉瑞将于协议生效日认购三生制药价值1亿美元的普通股股份。 国盛证券医药研究团队认为,此次三生制药与辉瑞的合作,其首付款、里程碑等均超预期;中国的第二 波创新药浪潮已经到来,这是中国创新药出海"从0到1"的浪潮。 SSGJ-707是三生制药基于CLF2专利平台开发的靶向PD-1/VEGF双特异性抗体,可同时抑制PD-1和 VEGF双靶点,具有同类最优(best-in-class) ...
港股科技ETF(159751)涨超1%,互联网巨头一季报亮眼支撑行情,三生制药首付款创国产创新药出海记录
Xin Lang Cai Jing· 2025-05-20 02:27
截至2025年5月20日 09:59,中证港股通科技指数(931573)强势上涨1.68%,成分股三生制药(01530)上涨 33.24%,零跑汽车(09863)上涨5.31%,信达生物(01801)上涨4.71%,再鼎医药(09688),小米集团- W(01810)等个股跟涨。港股科技ETF(159751)上涨1.48%,最新价报1.03元。拉长时间看,截至2025年5 月19日,港股科技ETF近1周累计上涨0.30%,涨幅排名可比基金1/5。 此外,成分股三生制药(01530.HK)及其全资附属公司沈阳三生制药有限责任公司(沈阳三生)与辉瑞公司 (辉瑞)订立了独家许可协议。根据协议,三生制药将PD-1/VEGF双特异性抗体(研发代码:SSGJ-707)的中 国外全球权益授权给辉瑞,同时辉瑞还获得了该产品在中国市场商业化的选择权。 招银国际认为,受益于创新药出海交易、国内集采政策优化、创新药丙类医保目录落地、医疗设备招标 复苏、内需复苏等积极因素推动,医药行业有望在2025年继续迎来估值修复。 港股科技ETF紧密跟踪中证港股通科技指数,中证港股通科技指数从港股通范围内选取50只市值较大、 研发投入较高且营收 ...
三生国健双抗新药授权辉瑞 科创板药企再次刷新国产创新药出海首付款纪录
news flash· 2025-05-20 02:23
三生国健双抗新药授权辉瑞 科创板药企再次刷新国产创新药出海首付款纪录 金十数据5月20日讯,5月20日,科创板创新药企业三生国健宣布,公司及关联方三生制药和沈阳三生共 同授予辉瑞PD-1/VEGF双特异性抗体SSGJ-707在全球(不包括中国大陆)的独家开发、生产、商业化 权利。辉瑞保留通过支付额外付款获得在中国大陆商业化许可产品的权利。根据协议,辉瑞将支付12.5 亿美元不可退还且不可抵扣的首付款,最高可达48亿美元的开发、监管批准和销售里程碑付款,以及根 据授权地区产品销售额计算得到的两位数百分比的梯度销售分成。该笔授权交易的"12.5亿美元首付 款"再次刷新国产创新药出海首付款金额纪录,也标志着科创板创新药企业的研发实力再次获得国际顶 尖医药公司认可,达成国内药企迈向全球市场的又一里程碑。 (上证报) ...
三生制药全球授权,港股通科技ETF(513860)上涨1.29%
Xin Lang Cai Jing· 2025-05-20 02:13
招银国际认为,受益于创新药出海交易、国内集采政策优化、创新药丙类医保目录落地、医疗设备招标 复苏、内需复苏等积极因素推动,医药行业有望在2025年继续迎来估值修复。 港股通科技ETF紧密跟踪中证港股通科技人民币指数,中证港股通科技指数从港股通范围内选取50只市 值较大、研发投入较高且营收增速较好的科技龙头上市公司证券作为指数样本,以反映港股通内科技龙 头上市公司证券的整体表现。 截至2025年5月20日 09:43,港股通科技ETF(513860)上涨1.29%,最新价报0.71元,成交2075.11万元。 成分股方面,三生制药涨超29%,信达生物、再鼎医药、零跑汽车涨超4%。 消息面上,2025年5月19日,三生制药(01530.HK)及其全资附属公司沈阳三生制药有限责任公司(沈阳三 生)与辉瑞公司(辉瑞)订立了独家许可协议。根据协议,三生制药将PD-1/VEGF双特异性抗体(研发代 码:SSGJ-707)的中国外全球权益授权给辉瑞,同时辉瑞还获得了该产品在中国市场商业化的选择权。 拉长时间看,截至5月19日,港股通科技ETF近1周日均成交1.89亿元,居可比基金第一。 规模方面,港股通科技ETF最新规模达 ...
三生制药涨超30%,与辉瑞达成首付款12.5亿美元协议!T+0交易的港股通创新药ETF(159570)涨超3.6%,近60日净流入超22亿元!
Xin Lang Cai Jing· 2025-05-20 02:13
Group 1 - The Hong Kong stock market opened strong on May 20, with the Hong Kong Innovation Drug ETF (159570) rising over 3.6% and quickly surpassing a transaction volume of 4 billion [1] - The Hong Kong Innovation Drug ETF has seen a net inflow of over 2.2 billion in the last 60 days, indicating strong investor interest in the innovative drug sector [1] - On May 20, 2023, 3SBio announced a partnership with Pfizer, granting exclusive rights for the global development, production, and commercialization of its proprietary PD-1/VEGF bispecific antibody SSGJ-707 outside of mainland China [1] Group 2 - According to the agreement, 3SBio will receive a non-refundable upfront payment of $1.25 billion and up to $4.8 billion in milestone payments related to development, regulatory approval, and sales [1] - 3SBio will also receive a tiered sales royalty based on product sales in the licensed territories, and Pfizer will purchase $100 million worth of common stock in 3SBio upon the agreement's effective date [1] - The majority of the popular component stocks in the Hong Kong Innovation Drug ETF saw gains, with 3SBio rising over 30% [3] Group 3 - The 2025 ASCO Annual Meeting, recognized as a major oncology conference, will take place from May 30 to June 3, 2025, in Chicago, Illinois [3] - Several innovative drug companies are expected to disclose significant data at the ASCO meeting, with 3SBio set to present Phase 2 data for SSGJ-707 in non-small cell lung cancer [3] - The recent U.S. drug price reduction executive order may lead to global pharmaceutical companies adjusting their pricing strategies, with China's innovative drugs potentially becoming a preferred choice for business development transactions [4][5] Group 4 - The U.S. executive order aims to provide the best price for prescription drugs, but its short-term impact on innovative drug prices is expected to be limited due to the lack of implementation details and potential legal challenges [5] - Long-term pressures on U.S. drug prices are anticipated as Medicare and Medicaid expenditures are projected to grow from $1.5 trillion to $2.0 trillion from 2020 to 2024, with an annual growth rate of 7.0% [5] - The Hong Kong Innovation Drug ETF (159570) has a high concentration in innovative drugs, with over 85% of its weight in innovative drug stocks, making it a prominent player in the market [6]